- Type 1 diabetes is an autoimmune condition where the body’s immune system attacks and destroys insulin-producing beta cells in the pancreas, leading to an insulin deficiency. Type 2 diabetes occurs when the body becomes resistant to insulin or doesn't produce enough. Insulin therapy is used to regulate blood glucose levels in both conditions, improving glycemic control and preventing complications like cardiovascular diseases, kidney failure, and nerve damage
- Type 1 diabetes (T1D) is typically diagnosed in childhood or adolescence and requires lifelong insulin therapy, as the pancreas produces little to no insulin. It is an autoimmune disorder where the immune system mistakenly attacks insulin-producing beta cells. Type 2 Diabetes (T2D) is more common and primarily occurs in adults, although it is increasingly seen in children due to rising obesity rates. T2D is characterized by insulin resistance, where the body does not use insulin effectively. Over time, the pancreas cannot produce enough insulin to maintain normal blood glucose levels. Both types of diabetes require regular monitoring and insulin therapy to manage blood sugar levels effectively. Insulin treatment helps in preventing long-term complications like retinopathy, neuropathy, and cardiovascular diseases, improving the overall quality of life for patients
- The U.S. stands out as one of the dominant region for Insulin Market for Type 1 And Type 2 Diabetes, driven by its advanced healthcare infrastructure and high adoption of innovative insulin delivery technologies
- For instance, U.S. continues to lead in the use of insulin pumps and continuous glucose monitoring systems, enabling better diabetes management
- With a growing focus on diabetes treatment and patient-centric solutions, the region drives significant advancements in insulin therapies, contributing greatly to North America market growth.
